Drug intelligence / Profile preview

erlotinib + figitumumab

Development stage: Discontinued
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of erlotinib, an EGFR tyrosine kinase inhibitor, and figitumumab, a fully human IgG2 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R). This combination was investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with advanced, pretreated, nonadenocarcinoma NSCLC. Clinical development of this combination was discontinued after phase III trials showed no improvement in overall survival compared to erlotinib alone.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + figitumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + figitumumab.

Explore the full profile